1
|
Wegert A, Monnee M, de Graaf W, van Holst F, Bolcato G, Díaz JL, Dordal A, Portillo-Salido E, Reinoso RF, Yeste S, Torrens A, Almansa C. Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Ca vα2δ-1 Subunit of Voltage-Gated Calcium Channel and the μ-Opioid Receptor. ChemMedChem 2024; 19:e202300473. [PMID: 38230842 DOI: 10.1002/cmdc.202300473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Revised: 12/05/2023] [Indexed: 01/18/2024]
Abstract
The synthesis and pharmacological activity of a new series of dual ligands combining activities towards the α2δ-1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the μ-opioid receptor (MOR) as novel pain therapeutics are reported. A careful exploration of the pharmacophores related to both targets, which in principle had few common characteristics, led to the design of novel compounds exhibiting both activities. The construction of the dual ligands started from published Cavα2δ-1 ligands, onto which MOR ligand pharmacophoric elements were added. This exercise led to new amino-acidic substances with good affinities on both targets as well as good metabolic and physicochemical profiles and low potential for drug-drug interactions. A representative compound, (2S,4S)-4-(4-chloro-3-(((cis)-4-(dimethylamino)-4-phenylcyclohexyl)methyl)-5-fluorophenoxy)pyrrolidine-2-carboxylic acid, displayed promising analgesic activities in several in vivo pain models as well as a reduced side-effect profile in relation to morphine.
Collapse
Affiliation(s)
- Anita Wegert
- Symeres, Kerkenbos 1013, 6546 BB, Nijmegen, The, Netherlands
| | - Menno Monnee
- Symeres, Kerkenbos 1013, 6546 BB, Nijmegen, The, Netherlands
| | - Wouter de Graaf
- Symeres, Kerkenbos 1013, 6546 BB, Nijmegen, The, Netherlands
| | - Frank van Holst
- Symeres, Kerkenbos 1013, 6546 BB, Nijmegen, The, Netherlands
| | | | - José Luis Díaz
- WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028, Barcelona, Spain
| | - Albert Dordal
- WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028, Barcelona, Spain
| | | | - Raquel F Reinoso
- WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028, Barcelona, Spain
| | - Sandra Yeste
- WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028, Barcelona, Spain
| | - Antoni Torrens
- WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028, Barcelona, Spain
| | - Carmen Almansa
- WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028, Barcelona, Spain
| |
Collapse
|
2
|
Díaz JL, Cuevas F, Pazos G, Álvarez-Bercedo P, Oliva AI, Sarmentero MÁ, Font D, Jiménez-Aquino A, Morón M, Port A, Pascual R, Dordal A, Portillo-Salido E, Reinoso RF, Vela JM, Almansa C. Bicyclic Diazepinones as Dual Ligands of the α2δ-1 Subunit of Voltage-Gated Calcium Channels and the Norepinephrine Transporter. J Med Chem 2021; 64:2167-2185. [PMID: 33591743 DOI: 10.1021/acs.jmedchem.0c01867] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The synthesis and pharmacological activity of a new series of bicyclic diazepinones with dual activity toward the α2δ-1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET) are reported. Exploration of the positions amenable for substitution on a nonaminoacidic Cavα2δ-1 scaffold allowed the identification of favorable positions for the attachment of NET pharmacophores. Among the patterns explored, attachment of the 2-ethylamino-9-methyl-6-phenyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-e][1,4]diazepin-5-one framework to the meta-position of the phenyl ring of the 3-methylamino-1-phenylpropoxy and 3-methylamino-1-thiophenylpropoxy moieties provided dual compounds with excellent NET functionality. Alternative bicyclic frameworks were also explored, and some lead molecules were identified, which showed a balanced dual profile and exhibited good ADMET properties.
Collapse
Affiliation(s)
- José Luis Díaz
- ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain
| | - Félix Cuevas
- Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain
| | - Gonzalo Pazos
- Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain
| | - Paula Álvarez-Bercedo
- Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain
| | - Ana I Oliva
- Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain
| | - M Ángeles Sarmentero
- Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain
| | - Daniel Font
- Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain
| | - Agustín Jiménez-Aquino
- Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain
| | - María Morón
- Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain
| | - Adriana Port
- ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain
| | - Rosalía Pascual
- ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain
| | - Albert Dordal
- ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain
| | - Enrique Portillo-Salido
- ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain
| | - Raquel F Reinoso
- ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain
| | - José Miguel Vela
- ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain
| | - Carmen Almansa
- ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain
| |
Collapse
|
3
|
Calvo D, Vázquez MJ, Ashby C, Domínguez JM. Kinetic considerations on the development of binding assays in single-addition mode: application to the search for α2δ1 modulators. JOURNAL OF BIOMOLECULAR SCREENING 2012; 17:1041-9. [PMID: 22772056 DOI: 10.1177/1087057112452318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The development of assays in single-addition mode is of great interest for screening purposes given the multiple advantages of minimizing the number of intervention steps. Binding assays seem to be more prone to this attractive format because no functional biological activity is taking place but instead a biophysical process, whose dynamics seem easier to control without introducing significant alterations, is happening. Therefore, single-addition assays based on the displacement of prebound labeled ligands can be conceived, but careful kinetic considerations must still be taken to maximize the sensitivity of the assay and to avoid jeopardizing the identification of compounds with slow-binding kinetics. This article shows the development of a single-addition, displacement-based binding assay intended to identify modulators that act by binding to the gabapentin site of the ion channel regulatory protein α2δ1. After studying the kinetics of gabapentin binding and the influence they might have on the assay sensitivity, the best conditions were identified, and the sensitivity was compared with that of the more classical two-additions competition-based assay. Although the present study focuses on α2δ1 and its interaction with gabapentin, the rationale and the methodology followed are of broad purpose and can be applied to virtually every binding assay.
Collapse
Affiliation(s)
- David Calvo
- Biological Reagents and Assay Development Department, GlaxoSmithKline, Madrid, Spain
| | | | | | | |
Collapse
|
4
|
Surry DS, Buchwald SL. Dialkylbiaryl Phosphines in Pd-Catalyzed Amination: A User's Guide. Chem Sci 2011; 2:27-50. [PMID: 22432049 PMCID: PMC3306613 DOI: 10.1039/c0sc00331j] [Citation(s) in RCA: 1185] [Impact Index Per Article: 91.2] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Dialkylbiaryl phosphines are a valuable class of ligand for Pd-catalyzed amination reactions and have been applied in a range of contexts. This review attempts to aid the reader in the selection of the best choice of reaction conditions and ligand of this class for the most commonly encountered and practically important substrate combinations.
Collapse
Affiliation(s)
- David S. Surry
- Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. Fax: +1-617-253-3297; Tel: +1-617-253-1885
| | - Stephen L. Buchwald
- Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. Fax: +1-617-253-3297; Tel: +1-617-253-1885
| |
Collapse
|
5
|
Csuk R, Barthel A, Raschke C, Kluge R, Ströhl D, Trieschmann L, Böhm G. Synthesis of Monomeric and Dimeric Acridine Compounds as Potential Therapeutics in Alzheimer and Prion Diseases. Arch Pharm (Weinheim) 2009; 342:699-709. [DOI: 10.1002/ardp.200900065] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
6
|
Surry D, Buchwald S. Biarylphosphanliganden in der palladiumkatalysierten Aminierung. Angew Chem Int Ed Engl 2008. [DOI: 10.1002/ange.200800497] [Citation(s) in RCA: 500] [Impact Index Per Article: 31.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
7
|
Abstract
Palladium-catalyzed amination reactions of aryl halides have undergone rapid development in the last 12 years, largely driven by the implementation of new classes of ligands. Biaryl phosphanes have proven to provide especially active catalysts in this context. This Review discusses the application of these catalysts in C-N cross-coupling reactions in the synthesis of heterocycles and pharmaceuticals, in materials science, and in natural product synthesis.
Collapse
Affiliation(s)
- David S Surry
- Department of Chemistry, Room 18-490, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | |
Collapse
|
8
|
Burgos-Lepley CE, Thompson LR, Kneen CO, Osborne SA, Bryans JS, Capiris T, Suman-Chauhan N, Dooley DJ, Donovan CM, Field MJ, Vartanian MG, Kinsora JJ, Lotarski SM, El-Kattan A, Walters K, Cherukury M, Taylor CP, Wustrow DJ, Schwarz JB. Carboxylate bioisosteres of gabapentin. Bioorg Med Chem Lett 2006; 16:2333-6. [PMID: 15946842 DOI: 10.1016/j.bmcl.2005.05.016] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2005] [Revised: 05/02/2005] [Accepted: 05/04/2005] [Indexed: 11/29/2022]
Abstract
A series of carboxylate bioisosteres of structures related to gabapentin 1 have been prepared. When the carboxylate was replaced by a tetrazole, this group was recognized by the alpha2-delta protein. Further characterization of alpha2-delta binding compounds 14a and 14b revealed a similar pattern of functional in vitro and in vivo activity to gabapentin 1.
Collapse
Affiliation(s)
- Carmen E Burgos-Lepley
- Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Schwarz JB, Gibbons SE, Graham SR, Colbry NL, Guzzo PR, Le VD, Vartanian MG, Kinsora JJ, Lotarski SM, Li Z, Dickerson MR, Su TZ, Weber ML, El-Kattan A, Thorpe AJ, Donevan SD, Taylor CP, Wustrow DJ. Novel Cyclopropyl β-Amino Acid Analogues of Pregabalin and Gabapentin That Target the α2-δ Protein. J Med Chem 2005; 48:3026-35. [PMID: 15828841 DOI: 10.1021/jm0491086] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
As part of a program aimed at generating compounds with affinity for the alpha(2)-delta subunit of voltage-gated calcium channels, several novel beta-amino acids were prepared using an efficient nitroalkane-mediated cyclopropanation as a key step. Depending on the ester that was chosen, the target amino acids could be prepared in as few as three steps. The cyclopropyl amino acids derived from ketones proved to be potent binders of the alpha(2)-delta subunit of voltage-gated calcium channels, but did not interact with the large neutral amino acid system L (leucine) transporter. Anticonvulsant effects were observed in vivo with compound 34 but only after intracerebroventricular (icv) administration, presumably due to inadequate brain concentrations of the drug being achieved following oral dosing. However, pregabalin 1 was active in the DBA/2 model after oral (and icv) dosing, supporting a hypothesis that active transport is a prerequisite for such zwitterionic species to cross the blood-brain barrier.
Collapse
Affiliation(s)
- Jacob B Schwarz
- Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|